AstraZeneca Gets Fast Imfinzi Review For SCLC
Will Compete With Roche’s Tecentriq
Executive Summary
The drug major has won a priority review for Imfinzi in small cell lung cancer from the FDA. If approved, the new indication could add $1bn to sales of the checkpoint inhibitor
You may also be interested in...
AstraZeneca’s Calquence Catches Up With Imbruvica’s CLL Claim
AZ is counting on Calquence’s safety profile to gain ground against AbbVie/J&J’s blockbuster BTK inhibitor Imbruvica.
First Filing, In Japan, For Daiichi’s Lead ADC As Others Progress
In a further positive step for its oncology ambitions, Japanese company files first submission for promising lead antibody-drug conjugate, partnered globally with AstraZeneca, while other pipeline ADCs mark development progress.
BMS SCLC Chances Dive After Opdivo, Yervoy Combo Flunks Checkmate-451
BMS's Phase III Checkmate-451 combo trial with Opdivo and Yervoy misses its endpoint for small cell lung cancer in overall survival, building on recent disappointment caused by the failure of Checkmate-331.